Stratatech's genetically engineered skin tissue kills drug-resistant bacteria in mice - UPDATE
This article was originally published in Clinica
Executive Summary
Artificial skin grafts produced by regenerative medicine firm Stratatech have been shown to dramatically reduce bacterial infection, following genetic modification of the cells from which they are composed. The skin substitute product, which is based on the firm's core technology, StrataGraft, is efficacious against pathogen species that cannot be killed by antibiotics.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.